GPGrossPatternRESEARCH SYSTEM
SEC CHECK OPERATIONAL
GROSSPATTERN / FUNDAMENTAL STATE / POINT IN TIME

FHN · Sep 30, 2022

FIRST HORIZON CORP. A multidimensional configuration derived from the filing available at this observation—never a composite score or recommendation.

STATE CAPABILITYLEVEL 3[email protected]
Inspectable configuration

State dimensions

Filing0000036966-22-000075Bank
Sequential deposit growth0thOwn-history percentile · N=18
Evidence method

Sequential · gp.financial.deposits

-6.43% · CORE · VALID

Net-income growth53thOwn-history percentile · N=15
Evidence method

Yoy · gp.fundamentals.net_income

14.22% · CORE · VALID

Interest-expense growth93thOwn-history percentile · N=15
Evidence method

Yoy · gp.financial.interest_expense

73.17% · CORE · VALID

Cash and equivalents92thOwn-history percentile · N=12
Evidence method

Level · gp.fundamentals.cash

$1.9B · CORE · VALID

Sequential loan growth57thOwn-history percentile · N=14
Evidence method

Sequential · gp.financial.loans

1.40% · CORE · VALID

As-filed lineage

Fundamental state history

Each observation is tied to the filing and facts available at that report date. Amendments remain separate.

History31 statesSelf-history eligible
Period transition

What moved in the state?

Deposit Growth Decreased
Previous
-4.81%
Current
-6.43%
Delta
-1.62%
Earnings Growth Increased
Previous
-43.51%
Current
14.22%
Delta
57.73%
Funding Cost Growth Increased
Previous
-8.89%
Current
73.17%
Delta
82.06%
Liquidity Increased
Previous
$1.8B
Current
$1.9B
Delta
$38.0M
Loan Growth Decreased
Previous
2.79%
Current
1.40%
Delta
-1.38%
Self-history only

Previous similar states

Similarity compares compatible valid dimensions from this issuer's own point-in-time history. No market-return claim is attached.

Not enough compatible prior states for a transparent self-history match.
Research Graph

Related governed research

Method Percentiles and historical matches use only observations available at each point in time. Missing dimensions remain missing. Public price outcomes and cross-market analogues are deliberately absent.